SDMF Implementation Project
ID: 355269Type: Posted
Overview

Buyer

National Institute of Corrections (USDOJ-BOP-NIC)

Award Range

$0 - $200K

Eligible Applicants

Others

Funding Category

Other

Funding Instrument

Cooperative Agreement

Opportunity Category

Other

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355269
Timeline
    Description

    The National Institute of Corrections (NIC) is announcing the SDMF Implementation Project, which will be funded through a cooperative agreement aimed at facilitating the Structured Decision-Making Framework Initiative. This opportunity is not a request for applications but serves to inform potential applicants that NIC intends to make an award without full competition, with a total estimated program funding of $200,000 and a single award expected. The project is significant for enhancing decision-making processes within correctional systems, and interested parties can reach out to Cameron D. Coblentz at ccoblentz@bop.gov or by phone at 202-514-0053 for further information. The application deadline is set for July 15, 2024.

    Point(s) of Contact
    ccoblentz@bop.gov
    Files
    No associated files provided.
    Similar Opportunities
    Behavioral Health Partnership for Early Diversion of Adults and Youth
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is forecasting a grant opportunity titled "Behavioral Health Partnership for Early Diversion of Adults and Youth." This program aims to establish or expand initiatives that divert individuals with mental illness or co-occurring disorders from the criminal or juvenile justice systems to community-based mental health and substance use disorder services prior to arrest and booking. Such programs are crucial for enhancing public health and safety by providing necessary support to vulnerable populations. The estimated total program funding is $2 million, with approximately six awards expected, and interested applicants can reach out to Roxanne Castenada at roxanne.castenada@samhsa.hhs.gov or (240) 276-1917 for further information. The synopsis is anticipated to be posted on December 16, 2024, for the fiscal year 2025.
    Notice of Intent to Publish a Funding Opportunity for NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity titled "NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity," which aims to support research initiatives that address the intersection of substance use and racial equity. This grant program, utilizing the DP1 activity code, is designed to foster meaningful collaborations and innovative projects in this critical area of health research. With an estimated total program funding of $3.5 million and an award ceiling of $700,000, the anticipated application period will open in Fall 2025, following the expected publication of the notice of funding opportunity in Spring 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of October 14, 2025, with awards expected to be made by July 1, 2026.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative aims to provide statistical expertise for the design, conduct, and data management of multi-center clinical trials, particularly focusing on late-phase treatment trials across various cancer types and patient demographics. The funding, estimated at $47 million, will support approximately five awards, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, interested applicants should prepare their proposals in advance of the anticipated timeline.
    Notice of Intent to Publish a Funding Opportunity Announcement for TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT), aimed at advancing research on Temporomandibular Disorders (TMD). This initiative seeks to establish a national, interdisciplinary collaborative that will enhance TMD research, improve clinical care, and train future researchers in the field. The funding opportunity will provide a total of $7 million, with an award ceiling of $3.5 million for up to two cooperative agreements, and is expected to be published in Summer 2024, with applications due in Winter 2024. Interested applicants should prepare for the anticipated collaboration and project development in advance of the expected award date of July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.
    Projects of National Significance: Empowering Individuals
    Administration for Community Living
    The Administration for Community Living is forecasting a funding opportunity titled "Projects of National Significance: Empowering Individuals," aimed at enhancing the lives of individuals with intellectual and developmental disabilities (ID/DD) and their families. This initiative, supported by the Developmental Disabilities Assistance and Bill of Rights Act, seeks to empower these individuals through policy advocacy, leadership development, and increased knowledge of available supports, ultimately fostering their full participation in community life. The program anticipates awarding five cooperative agreements, with funding amounts ranging from $300,000 to $375,000, totaling an estimated $1,875,000, and interested applicants must be private institutions of higher education or eligible faith-based and community organizations. For further details, applicants can contact Larissa Crossen at (202) 795-7333 or via email at larissa.crossen@acl.hhs.gov, with proposals expected to be submitted between March 31, 2024, and May 30, 2024, and awards anticipated by September 1, 2024.
    Notice of Intent to Publish a Funding Opportunity Announcement for Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the establishment of a Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC) as part of its Somatic Cell Genome Editing (SCGE) program. The objective of this initiative is to accelerate the development of genome editing therapeutic agents by facilitating Investigational New Drug (IND) application enabling studies, establishing regulatory approval pathways, and disseminating successful strategies for initiating first-in-human clinical trials. This funding opportunity is crucial for advancing innovative therapeutic approaches in health, with an estimated total program funding of $2 million and the expectation of one award. Interested applicants can reach out to Dr. Marrah Lachowicz-Scroggins at SCGEprogram@od.nih.gov or by phone at 301-827-8229 for further details, with the anticipated application due dates in Summer 2022 and an estimated award date of April 1, 2023.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIDA Animal Genomics Program (U01), aimed at exploring the genetic and molecular factors associated with substance use disorders (SUD). This cooperative agreement encourages research that identifies genetic, genomic, and epigenetic variants influencing addictive behaviors and related comorbidities, utilizing diverse methodologies such as multi-omics and artificial intelligence. The program is open to a wide range of eligible applicants, including higher education institutions and nonprofit organizations, with no budget cap for proposals, although budgets should reflect actual project needs. Applications are due by February 12, 2027, with an opening date for submissions on January 11, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.